From biologic to biologic to biologic: Lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis

Australasian Journal of Dermatology

Volumn 49, Issue 3, 2008, Pages 152-155

  Yip, Leona ^a   Harrison, Shannon ^b   Foley, Peter ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b NONE

Author keywords

Efalizumab; Erythroderma; Etanercept; Infliximab

Indexed keywords

ALEFACEPT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ONERCEPT; PREDNISOLONE;

ADULT; ARTICLE; CASE REPORT; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MALE; PHOTOTHERAPY; PSORIASIS AREA AND SEVERITY INDEX SCORE; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; SCORING SYSTEM; ULTRAVIOLET B RADIATION;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 47349093706     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2008.00463.x     Document Type: Article

References (10)

1. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. 2002 46 : 1 23.
2. Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, Papp K, Rundle AC, Toth D. Relapse, rebound, and psoriasis adverse events: an advisory group report. J. Am. Acad. Dermatol. 2006 54 : S171 81.
3. Menter A, Hamilton TK, Toth DP, Leung HM, Wetherill G, Hennessey B, Garovoy M, Kwon P, Pariser DM. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study. Int. J. Dermatol. 2007 46 : 637 48.
4. de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, Shojania K, Martinka M, Dutz JP. Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch. Dermatol. 2007 143 : 223 31.
5. Haitz KA, Kalb RE. Infliximab in the treatment of psoriasis in patients previously treated with etanercept. J. Am. Acad. Dermatol. 2007 57 : 120 5.
6. Leonardi CL. Efalizumab: an overview. J. Am. Acad. Dermatol. 2003 49 : S98 104.
7. Haider AS, Cardinale IR, Whynot JA, Krueger JG. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J. Investig. Dermatol. Symp. Proc. 2007 12 : 9 15.
8. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. 2003 349 : 2004 13.
9. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005 366 : 1367 74.
10. Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Bravo Vergel Y et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol. Assess. 2006 10 : 1 252.